Recursion Pharmaceuticals clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-21
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.
- Minor: ELUCIDATE · GTAEXS617 · Advanced Solid Tumors Enrollment closed, study ongoing
- Notable: DAHLIA · REC-1245 · Unresectable, Locally Advanced, or Metastatic Cancer Primary and study completion pushed from Oct 30, 2028 to Jul 2029
- Notable: SYCAMORE · Symptomatic Cerebral Cavernous Malformation Trial of REC-994 Results posted: Oct 22, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 2 | |
| Phase 1/2 | 4 |
Disease areas by active trials, top 10 of 19
Breast Cancer (2) · Head & Neck Cancer (2) · Lung Cancer (2) · Non-Small Cell Lung Cancer (NSCLC) (2) · Ovarian Cancer (2) · Triple-Negative Breast Cancer (2) · Chronic Lymphocytic Leukemia (CLL) (1) · Colorectal Cancer (1) · DLBCL (1) · Follicular Lymphoma (1)
Get alerts when Recursion Pharmaceuticals's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.